Jul 2, 2026 – 12.00pmAn Australian company developing a new cancer-fighting technology that takes cells from healthy donors and stores them in large batches at a fraction of the cost of traditional immunotherapies that use a patient’s own blood will start human trials of the emerging immunotherapy this quarter.Despite a board spill three months ago, which saw its chief executive and two directors removed, ASX-listed Arovella Therapeutics said it is on the cusp of a breakthrough in cancer treatments that will offer a cheaper alternative to CAR-T therapies, which start at $700,000 per patient.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Fetching latest articles